Ian Gaudet, PhD Miltenyi Biotec, Inc.

Dr. Ian Gaudet studied Bioengineering at the University of California, San Diego, and received his doctorate in Biomedical Engineering jointly from Rutgers University and the University of Medicine and Dentistry of New Jersey. Following his Ph.D., Dr. Gaudet worked for Progenitor Cell Therapy (PCT) where he was the Sr. Engineer and then Director of Innovation and Engineering, leading a scientific and engineering team in support of design, development, and implementation of clinical cell therapy manufacturing processes, as well as cell therapy commercialization strategy consulting. Dr. Gaudet led multiple new client projects from tech transfer, development, and into clinical manufacturing, including multiple hematopoietic stem cell therapies. He also led the development efforts for the first CliniMACS Prodigy-based commercial cell therapy into FDA-approved clinical trials.  He joined Miltenyi Biotec, Inc. (MBI) in 2016 and is currently the Director of Process Development at MBI’s Sunnyvale, CA, cell therapy CDMO facility, working to bring new therapies into the clinic while ensuring long term commercial feasibility.